WMT

123.41

+0.33%↑

COST

996.2

+1.33%↑

144.86

+1.51%↑

76.38

+0.94%↑

164.77

+0.72%↑

WMT

123.41

+0.33%↑

COST

996.2

+1.33%↑

144.86

+1.51%↑

76.38

+0.94%↑

164.77

+0.72%↑

WMT

123.41

+0.33%↑

COST

996.2

+1.33%↑

144.86

+1.51%↑

76.38

+0.94%↑

164.77

+0.72%↑

WMT

123.41

+0.33%↑

COST

996.2

+1.33%↑

144.86

+1.51%↑

76.38

+0.94%↑

164.77

+0.72%↑

WMT

123.41

+0.33%↑

COST

996.2

+1.33%↑

144.86

+1.51%↑

76.38

+0.94%↑

164.77

+0.72%↑

Home・Akciju saraksts・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Slēgts

SektorsPatēriņa aizsardzības

3.79 4.12

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.61

Max

3.85

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.9M -10M
Pārdošana	-5.3M 31M
Peļņas marža	-32.116
Darbinieki	400

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+77.6% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. jūn.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-112M 130M
Iepriekšējā atvēršanas cena	-0.33
Iepriekšējā slēgšanas cena	3.79

Ziņu noskaņojums

By Acuity

72%

28%

121 / 131 Rangs Consumer defensive

Lifecore Biomedical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. marts 23:15 UTC

Galvenie ziņu notikumi

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

2026. g. 30. marts 22:36 UTC

Galvenie ziņu notikumi

Australian Government Rules Out Boots on the Ground in the Middle East

2026. g. 30. marts 22:13 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

2026. g. 30. marts 21:00 UTC

Peļņas

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

2026. g. 30. marts 20:15 UTC

Galvenie ziņu notikumi

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

2026. g. 30. marts 23:40 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. marts 23:40 UTC

Tirgus saruna

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

2026. g. 30. marts 23:36 UTC

Tirgus saruna

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

2026. g. 30. marts 23:12 UTC

Tirgus saruna

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

2026. g. 30. marts 22:49 UTC

Tirgus saruna

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

2026. g. 30. marts 22:44 UTC

Tirgus saruna

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

2026. g. 30. marts 22:43 UTC

Tirgus saruna

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

2026. g. 30. marts 22:42 UTC

Tirgus saruna

South32 Should Go for Growth, Says New Bull -- Market Talk

2026. g. 30. marts 22:18 UTC

Tirgus saruna

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

2026. g. 30. marts 22:05 UTC

Tirgus saruna

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

2026. g. 30. marts 21:58 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Financial Agrees to Buy Bell Partners for $350M

2026. g. 30. marts 21:39 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

2026. g. 30. marts 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

2026. g. 30. marts 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

2026. g. 30. marts 21:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. marts 21:25 UTC

Tirgus saruna

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

2026. g. 30. marts 21:03 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

2026. g. 30. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 30. marts 20:09 UTC

Peļņas

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

2026. g. 30. marts 20:00 UTC

Galvenie ziņu notikumi

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Salīdzinājums

Cenas izmaiņa

Lifecore Biomedical Inc Prognoze

Cenas mērķis

By TipRanks

77.6% augšup

Prognoze 12 mēnešiem

Vidējais 6.5 USD 77.6%

Augstākais 9 USD

Zemākais 5 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Lifecore Biomedical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Lifecore Biomedical Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

121 / 131 Rangs Patēriņa aizsardzības

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.